aRaloxifene reduces risk of endometrial cancer

	Tweet

While raloxifene and tamoxifen are similarly effective in reducing breast cancer risk, raloxifene also appears to lower the risk of developing endometrial cancer, researchers report in the September 1st issue of the Journal of Clinical Oncology.

“These data are important,” lead investigator Dr. Angela DeMichele told Reuters Health, “because they suggest a critical difference between tamoxifen and raloxifene that could help physicians in tailoring therapy to the patient.” She added, “A randomized clinical trial has shown that the drugs are roughly equivalent in terms of their ability to prevent breast cancer.”

Raloxifene and tamoxifen are two drug used to reduce the risk of invasive breast cancer in high-risk women by blocking the effects of estrogen on breast tissue. Tamoxifen is also used as a type of maintenance therapy for women who have already been treated for early breast cancer with surgery, radiation, and/or chemotherapy to reduce the risk of recurrence. Raloxifene is also used to treat osteoporosis.

To examine the effect of raloxifene and tamoxifen on endometrial cancer risk, DeMichele of the University of Pennsylvania, Philadelphia, and colleagues examined data on 547 women who were diagnosed with cancer of the endometrium, t-al cancer and 1410 controls. The endometrium is the lining of the uterus.

Some 3.3 percent of the cancer patients had taken raloxifene compared to 6.6 percent of the controls. Corresponding proportions for tamoxifen were 6.2 percent and 2.4 percent.

After adjusting the data for the effects of other risk factors, the risk of endometrial cancer in raloxifene users was half that of nonusers. Conversely, tamoxifen users were three times more likely to develop endometrial cancer than were raloxifene users.

Given the similarity in protection against breast cancer, continued DeMichele, “a secondary benefit, like a reduction in the risk of endometrial cancer, may be very important to patients who have not had a hysterectomy and are concerned about the increased risk of endometrial cancer with tamoxifen.”

SOURCE: Journal of Clinical Oncology, September 1, 2008.

RELATED STORIES:
Black-white gap mars endometrial cancer survival   Internal radiotherapy better than external for quality of life in endometrial cancer patients   TGen and Washington University researchers discover new approach to treating endometrial cancer   Urinary tract cancer associated with Chinese herbal products containing aristolochic acid   Frequent Alcohol Consumption Increases Cancer Risk in Older Women   Acrylamide not linked to endometrial cancer   Oral contraceptives and IUDs protect against endometrial cancer   Ovaries can be saved in some endometrial cancers   Coffee may lower endometrial cancer risk   Treatment of endometrial cancer by laparoscopy gives better patient quality of life   Know the Signs of Endometrial Cancer   Significant Weight Gain in Adulthood Increased Risk for Endometrial Cancer   Obesity, early menopause tied to uterine cancer   Tea may prevent endometrial cancer, but needs study   Endometrial Cancer in Postmenopausal Women Using Estradiol-Progestin Therapy   Soy may lessen risk of endometrial, ovarian cancers   A potent suppressor of endometrial cancer is revealed   Endometrial Cancer: Often Curable When Caught Early   Supplemental Radiation Therapy Beneficial for Stage I Endometrial Cancer   Tooth Loss Linked to Esophageal, Head and Neck, and Lung Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]